NCT04132843: Novel MRI Techniques for the Characterization and Treatment Assessment of High Grade Brain Lesions

NCT04132843
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Early Phase 1
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older ¬† (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: 
Exclusions: Patients with prior chemotherapy or radiation treatment to brain
https://ClinicalTrials.gov/show/NCT04132843

Comments are closed.

Up ↑